Jatinder Lamba

About

Dr. Jatinder Lamba is currently the associate dean for research and graduate education in the UF College of Pharmacy and a professor in the Department of Pharmacotherapy and Translational Research. In 2022, she was appointed the Frank A. Duckworth Eminent Scholar Chair. She completed her post-doctoral training at St. Jude Children’s Research Hospital in Memphis, Tennessee, and has previously served as an Associate Professor at the University of Minnesota, where she was involved in the Department of Experimental and Clinical Pharmacology and directed the Pathway driven Pharmacogenomics; University of Minnesota Alliance (PUMA) Institute of Personalized Medicine. Her research focuses on the identification, characterization, and clinical validation of genomic and epigenomic markers that predict therapeutic outcomes in cancer patients. Her work spans from preclinical basic research using cell line models to translational and clinical phases involving multi-institute clinical trials. The long-term goal of her research is to integrate pharmacogenetic testing into clinical practice to enhance the safety and efficacy of drug therapy. Dr. Lamba’s pharmacogenomics research on anti-leukemic agents has been funded by NIH/NCI since 2008, with her current work focusing on the pharmacogenomics and epigenomics of cytarabine in pediatric AML patients. Her group is developing algorithms to incorporate genetic and epigenetic markers with other prognostic factors to advance precision medicine in…

Research topics

• Genetics
• Biology
• Medicine
• Internal medicine
• Cancer research
• Oncology
• Immunology
• Pharmacology
• Bioinformatics
• Cell biology

Selected publications

• PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics

  Pharmacogenetics and Genomics · 2020 · 51 citations

  Mitra-Ghosh, Taraswi; Callisto, Samuel P.; Lamba, Jatinder K.; Remmel, Rory P.; Birnbaum, Angela K.; Barbarino, Julia M.; Klein, Teri E.; Altman, Russ B. Author Information

  DOI

• Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators

  Blood Cancer Discovery · 2021 · 36 citations

  -ITD and PRC2 mutations have different outcomes, demonstrating the impact of mutational composition on survival. Across the cohort, variability in outcomes of patients within isomutational subsets is influenced by transcriptional identity and the presence of a stem cell-like gene-expression signature. Integration of gene expression and somatic mutations leads to improved risk stratification. SIGNIFICANCE: .

  DOI

• SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw

  Journal of Bone and Mineral Research · 2020 · 24 citations

  > 0.8) with rs7896005. To validate the association between these SNPs and MRONJ, we genotyped these three SNPs on the germline DNA from 104 cancer patients of European ancestry treated with iv BPs (46 cases and 58 controls). Multivariable logistic regression analysis showed the minor alleles of these three SNPs were associated with lower odds for MRONJ. The odds ratios (95% confidence interval) and p values were 0.351 (0.164-0.751; p = 0.007) for rs3758391, 0.351 (0.164-0.751; p = 0.007) for rs9…

  DOI

• Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML

  Blood Advances · 2022 · 15 citations

  Senior authorCorresponding

  Etoposide is used to treat a wide range of malignant cancers, including acute myeloid leukemia (AML) in children. Despite the use of intensive chemotherapeutic regimens containing etoposide, a significant proportion of pediatric patients with AML become resistant to treatment and relapse, leading to poor survival. This poses a pressing clinical challenge to identify mechanisms underlying drug resistance to enable effective pharmacologic targeting. We performed a genome-wide CRISPR/Cas9 synthetic…

  PublisherOA PDFDOI

• A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials

  Leukemia · 2022 · 9 citations

  Senior authorCorresponding
  PublisherOA PDFDOI

Recent grants

• NIH Grant R21CA155524

  NIH · $439k · 2015

• Genomics of AML Prognosis

  NIH · $5.3M · 2008–2026

Frequent coauthors

• Stanley Pounds

  212 shared

• Xueyuan Cao

  University of Tennessee Health Science Center

  202 shared

• Jeffrey E. Rubnitz

  199 shared

• Raul C. Ribeiro

  St. Jude Children's Research Hospital

  182 shared

• Soheil Meshinchi

  175 shared

• Todd A. Alonzo

  Children's Oncology Group

  153 shared

• Susana C. Raimondi

  St. Jude Children's Research Hospital

  141 shared

• Alan S. Gamis

  Children's Mercy Hospital

  141 shared

Labs

• Department of Pharmacotherapy and Translational ResearchPI

Education

• Ph.D., Experimental and Clinical Pharmacology

  University of Minnesota

• Other

  St. Jude Children’s Research Hospital

Awards & honors

• Frank A. Duckworth Eminent Scholar Chair (2022)
• Pharmacogenomics SIG Chair at AACP (2013)
• Review grants for Italian Ministry of Health

Similar researchers at University of Florida

• Charles Peloquinh-84
• Yan Gongh-65
• Joseph Collinsh-61